Oncology Drugs

By targeting the physical mechanics of tumors rather than biochemical pathways, Myosin Therapeutics aims to conquer glioblastoma and court investors in NYC.

By bringing on a veteran dealmaker with deep isotope supply chain expertise, Actinium is positioning its Ac-225 pipeline for big pharma's aggressive M&A wave.

Pilatus Biosciences doses its first Hong Kong patient with PLT012, signaling a strategic shift toward metabolic immunotherapies and Asian clinical hubs.

Parabilis Medicines advances its first-in-class beta-catenin inhibitor into a new FAP cohort, signaling a paradigm shift from surgical intervention to systemic prevention.

Orum Therapeutics enters the clinic with a novel degrader-antibody conjugate, aiming to turn a historically toxic mechanism into a targeted lifeline for AML.

Following its 2024 Sanofi spin-off, Inhibrx Biosciences is preparing to unveil pivotal cancer trial data that could validate its multivalent protein platform.

The NMPA approval of a 6-month prostate cancer drug reveals how mid-tier biotechs navigate China's complex healthcare landscape via strategic partnerships.

CytoDyn is pivoting to oncology with its CCR5 inhibitor leronlimab. Upcoming Phase 2 data at ESMO 2026 could determine the biotech's financial survival.

Alpheus Medical's new clinical trial tackles butterfly glioblastoma, leveraging non-invasive ultrasound and strategic financing to disrupt oncology.

Survival rates for childhood cancer have soared from 25% in the 1960s to 87% today, fueled by precision medicine. Yet, a severe global equity gap persists.

Ahead of a critical 2027 data readout, Moleculin pitches a breakthrough leukemia drug while navigating a precarious financial runway.

A new peer-reviewed study validates RenovoRx's targeted catheter platform, offering a strategic bridge as the company approaches its 2027 Phase III readout.

Rakovina Therapeutics is teaming up with Celvion to leverage real-world AI data, aiming to bypass clinical hurdles and de-risk its ATR inhibitor pipeline.

Pliant Therapeutics taps veteran oncologist Dr. David Raben as CMO to steer its targeted ICI-refractory cancer program toward crucial 2027 clinical milestones.

NuCana's new European patent for its cancer drug NUC-7738 strengthens its global IP moat, backing its clinical push against PD-1 resistant melanoma into 2029.

Kyowa Kirin’s partnership with Knight Therapeutics to bring POTELIGEO to Latin America reveals the complex strategy required to conquer fragmented markets.

As Europe embraces small modular reactors and radiopharmaceuticals, Mirion Technologies shifts its flagship safety summit to capture a booming market.

Marathon Fusion proposes a novel supply chain hack using a stable precursor to solve the multi-decade shortage of a promising cancer-treating radioisotope.

Scancell leverages a costly $25M BlackRock debt facility to bridge a Nasdaq reverse merger and fuel a pivotal melanoma trial. Will the clinical data deliver?

A €12M Series A for German biotech ViferaXS highlights a strategic shift in European sovereign funding and the rise of the tech-bio equity playbook.